Top five ophthalmic business stories from first half of September
One of the most-read ophthalmic business stories from the first half of September was about a large fine for Novartis and Roche/Genentech in France.
Here are some other recent ophthalmic business articles that have run on Healio/OSN so far this month.
Novartis, Roche/Genentech face major fines from French regulatory authority
Novartis and Roche/Genentech are facing a combined 444 million euros in fines from the French Competition Authority for “abusive practices” intended to sustain sales of an expensive product. Read more.
VIDEO: Tarsus works to develop Demodex blepharitis treatment
In this video, Aziz Mottiwala, newly appointed chief commercial officer for Tarsus Pharmaceuticals, discusses the company’s plans to drive the development of its therapeutic for the treatment of Demodex blepharitis. Watch more.
Orasis Pharmaceuticals raises $30 million in financing
Orasis Pharmaceuticals has closed $30 million in Series C financing to advance its eye drop candidate for the treatment of presbyopia symptoms through phase 3 clinical trials. Read more.
AMA issues CPT codes for implantation of artificial iris
The AMA has issued three CPT codes for artificial iris implantation, according to a press release from Veo Ophthalmics. Read more.
Bausch Foundation report details charitable activities
The Bausch Foundation released its inaugural activity report, detailing the contributions and work the foundation put forth in its first 2.5 years, including raising nearly $20,000 in support of the Eye Bank Association of America. Read more.